Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics
- 461 Downloads
Chronic pseudomonal bronchopulmonary infections in cystic fibrosis patients are frequently controlled with inhaled antibiotics. Dry-powder inhalable antibiotics are an attractive alternative to nebulized medications. We produced and evaluated microparticles composed of dipalmitoylphosphatidylcholine, albumin, and lactose as a model system for intrapulmonary delivery of ceftazidime, ciprofloxacin, and several combinations of the two, none of which is presently available for inhalation. Microparticles containing one or both antibiotics were prepared by spray-drying. Their Anderson cascade impactor deposition profiles showed 10–30% fine particle fractions of the nominal dose. Microparticles containing varying amounts of each antibiotic showed statistically different deposition profiles. Aerodynamics and deposition of microparticles co-encapsulating both antibiotics were similar to those of single-drug microparticles with the same proportion of ciprofloxacin alone. The antipseudomonal activities of microparticles co-encapsulating half of the 50% effective concentration (EC50) of both ceftazidime and ciprofloxacin (5 mg of particles containing 5% ceftazidime and 10% ciprofloxacin) were at least additive compared to particles containing the EC50 of each antibiotic separately (5 mg of particles containing 10% ceftazidime or 5 mg of particles containing 20% ciprofloxacin). Co-encapsulation of the antibiotics in microparticles ensures co-deposition at desired ratios, improves the particles’ aerodynamics and fine particle fraction, as compared to microparticles with equivalent amounts of ceftazidime alone, and achieves additive antipseudomonal activity.
KEY WORDSco-encapsulation cystic fibrosis dry-powder inhalational delivery of antibiotics microparticles
We would like to express our gratitude to Henry Dorkin, MD for helpful insights. This work was supported by Cystic Fibrosis Foundation Research and Clinical Fellowship grant (TSIFAN02B0) to MDT and NIH GM073626 to DSK.
- 2.M. I. Gomez, and A. Prince. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol (2007).Google Scholar
- 4.B. W. Ramsey, M. S. Pepe, J. M. Quan, K. L. Otto, A. B. Montgomery, J. Williams-Warren, K. M. Vasiljev, D. Borowitz, C. M. Bowman, B. C. Marshall et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340(1):23–30 (1999).PubMedCrossRefGoogle Scholar
- 10.B. Laube. Aerosol delivery systems. In G. Loughlin, and H. Eigen (eds.), Respiratory Disease in Children: Diagnosis and Management, Williams and Wilkins, Baltimore, MD, 1994, pp. 721–729.Google Scholar
- 21.J. L. Burns, J. M. Van Dalfsen, R. M. Shawar, K. L. Otto, R. L. Garber, J. M. Quan, A. B. Montgomery, G. M. Albers, B. W. Ramsey, and A. L. Smith. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J. Infect. Dis. 179(5):1190–1196 (1999).PubMedCrossRefGoogle Scholar
- 34.H. Adi, P. M. Young, H. K. Chan, P. Stewart, H. Agus, and D. Traini. Cospray dried antibiotics for dry powder lung delivery. J Pharm Sci. (2007).Google Scholar
- 35.Gentamicin. Micromedex® Healthcare Series. Thomson MicromedexGoogle Scholar
- 36.Ciprofloxacin. Micromedex® Healthcare Series. Thomson MicromedexGoogle Scholar
- 37.Ceftazidime. Micromedex® Healthcare Series. Thomson MicromedexGoogle Scholar